Cingulate Inc. (CING) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US17248W3034
Cingulate Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -19.94 m USD |
| EBIT | -21.55 m USD |
| Net income | -22.45 m USD |
| Diluted EPS – continuing operations | -4.44 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
More stocks
- Ilyda SA (ILYDA.AT)
- Rans Entertainmen Indonesia Tbk (RANS.JK)
- Export Packing (002200.KS)
- JLS Co.Ltd (040420.KQ)
- Morefield Group N.V. (MORE.AS)
- Tekcore Co. Ltd (3339.TWO)
- PROKIDNEY CORP. (PROK)
- Huang Long Development Co Ltd (3512.TWO)
- Concorde International Group Ltd Class A Ordinary Shares (CIGL)
- LIQUIDMETAL TECHNOLOGIES INC (LQMT)
- Norbel Baby Co., Ltd (6844.TWO)
- TOPTEC Co. Ltd (108230.KQ)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.